Cargando…
Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain we...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640393/ https://www.ncbi.nlm.nih.gov/pubmed/29062235 http://dx.doi.org/10.2147/OTT.S141260 |
_version_ | 1783271035628421120 |
---|---|
author | Koutsoukos, Konstantinos Bamias, Aristotelis Tzannis, Kimon Espinosa Montaño, Marta Bozionelou, Vasiliki Christodoulou, Christos Stefanou, Dimitra Kalofonos, Haralabos Duran, Ignacio Papazisis, Konstantinos |
author_facet | Koutsoukos, Konstantinos Bamias, Aristotelis Tzannis, Kimon Espinosa Montaño, Marta Bozionelou, Vasiliki Christodoulou, Christos Stefanou, Dimitra Kalofonos, Haralabos Duran, Ignacio Papazisis, Konstantinos |
author_sort | Koutsoukos, Konstantinos |
collection | PubMed |
description | AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). RESULTS: In total, 31 patients were enrolled. Of these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37–5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47–13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54–19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). CONCLUSION: This study provides data exclusively on the sequence pazopanib–everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib–everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population. |
format | Online Article Text |
id | pubmed-5640393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56403932017-10-23 Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib Koutsoukos, Konstantinos Bamias, Aristotelis Tzannis, Kimon Espinosa Montaño, Marta Bozionelou, Vasiliki Christodoulou, Christos Stefanou, Dimitra Kalofonos, Haralabos Duran, Ignacio Papazisis, Konstantinos Onco Targets Ther Original Research AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). RESULTS: In total, 31 patients were enrolled. Of these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37–5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47–13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54–19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). CONCLUSION: This study provides data exclusively on the sequence pazopanib–everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib–everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population. Dove Medical Press 2017-10-06 /pmc/articles/PMC5640393/ /pubmed/29062235 http://dx.doi.org/10.2147/OTT.S141260 Text en © 2017 Koutsoukos et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Koutsoukos, Konstantinos Bamias, Aristotelis Tzannis, Kimon Espinosa Montaño, Marta Bozionelou, Vasiliki Christodoulou, Christos Stefanou, Dimitra Kalofonos, Haralabos Duran, Ignacio Papazisis, Konstantinos Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title | Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title_full | Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title_fullStr | Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title_full_unstemmed | Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title_short | Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
title_sort | real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640393/ https://www.ncbi.nlm.nih.gov/pubmed/29062235 http://dx.doi.org/10.2147/OTT.S141260 |
work_keys_str_mv | AT koutsoukoskonstantinos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT bamiasaristotelis realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT tzanniskimon realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT espinosamontanomarta realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT bozionelouvasiliki realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT christodoulouchristos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT stefanoudimitra realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT kalofonosharalabos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT duranignacio realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib AT papazisiskonstantinos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib |